{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:09:46Z","timestamp":1789578586916,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijcard.2026.134588","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T16:10:18Z","timestamp":1779811818000},"page":"134588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["GLP-1 receptor agonists associated with better cardiovascular outcomes in obese or diabetic patients with elevated Lp(a) levels: A Multicenter retrospective study"],"prefix":"10.1016","volume":"459","author":[{"given":"Ahmed K.","family":"Mahmoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham","family":"Sheashaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Killian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramzi","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Abdelnabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Simper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Lester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadi","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Arsanjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2026.134588_bb0005","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein (a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"Jama"},{"key":"10.1016\/j.ijcard.2026.134588_bb0010","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein (a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2026.134588_bb0015","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein (a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2026.134588_bb0020","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/MED.0000000000000237","article-title":"Lipoprotein (a): novel target and emergence of novel therapies to lower cardiovascular disease risk","volume":"23","author":"Tsimikas","year":"2016","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"10.1016\/j.ijcard.2026.134588_bb0025","article-title":"Lipoprotein (a) levels and vulnerable characteristics in nonculprit plaque in patients with acute coronary syndrome","volume":"43","author":"Kato","year":"2022","journal-title":"IJC Heart Vasc."},{"key":"10.1016\/j.ijcard.2026.134588_bb0030","article-title":"Lipoprotein (a) level is associated with plaque vulnerability in patients with coronary artery disease: an optical coherence tomography study","volume":"24","author":"Muramatsu","year":"2019","journal-title":"IJC Heart Vasc."},{"key":"10.1016\/j.ijcard.2026.134588_bb0035","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s10157-013-0875-8","article-title":"Causes and consequences of lipoprotein (a) abnormalities in kidney disease","volume":"18","author":"Kronenberg","year":"2014","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.ijcard.2026.134588_bb0040","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/bmj.304.6826.545","article-title":"Lipoprotein (a) in cirrhosis","volume":"304","author":"Feely","year":"1992","journal-title":"BMJ"},{"key":"10.1016\/j.ijcard.2026.134588_bb0045","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"46","author":"Mach","year":"2025","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2026.134588_bb0050","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1001\/jama.2025.2373","article-title":"Lipoprotein (a)","volume":"333","author":"Mora","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2026.134588_bb0055","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/eurjpc\/zwab171","article-title":"Statin therapy and lipoprotein (a) levels: a systematic review and meta-analysis","volume":"29","author":"de Boer","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.ijcard.2026.134588_bb0060","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-36204-7","article-title":"Impact of ezetimibe on plasma lipoprotein (a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Sahebkar","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijcard.2026.134588_bb0065","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jacl.2023.02.002","article-title":"Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein (a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial","volume":"17","author":"Ridker","year":"2023","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.ijcard.2026.134588_bb0070","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1161\/CIRCULATIONAHA.107.739938","article-title":"Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor\u2013dependent and\u2013independent pathways","volume":"117","author":"Ban","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2026.134588_bb0075","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2337\/db08-1193","article-title":"GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice","volume":"58","author":"Noyan-Ashraf","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.ijcard.2026.134588_bb0080","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/ATVBAHA.110.206425","article-title":"Glucagon-like peptide 1 prevents reactive oxygen species\u2013induced endothelial cell senescence through the activation of protein kinase A","volume":"30","author":"Oeseburg","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ijcard.2026.134588_bb0085","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.bbrc.2009.12.075","article-title":"Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression","volume":"391","author":"Ishibashi","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ijcard.2026.134588_bb0090","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/S0140-6736(25)01375-3","article-title":"Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: A prespecified analysis of the SELECT trial","volume":"406","author":"Deanfield","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2026.134588_bb0095","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2026.134588_bb0100","doi-asserted-by":"crossref","DOI":"10.1161\/circ.150.suppl_1.4145358","article-title":"Cardiovascular outcomes of Glucagon-Like Peptide 1 receptor agonists in patients with or without Diabetes Mellitus, a meta-analysis of randomized controlled trials","volume":"150","author":"Khan","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2026.134588_bb0105","series-title":"The effects of Glucagon-Like Peptide-1 receptor agonists on atherosclerotic plaque: Cytokine profile in diabetic individuals","author":"Hachu\u0142a","year":"2024"},{"key":"10.1016\/j.ijcard.2026.134588_bb0110","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/1755-5922.12000","article-title":"GLP-1 receptor agonists: effects on cardiovascular risk reduction","volume":"31","author":"Lorber","year":"2013","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.ijcard.2026.134588_bb0115","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2026.134588_bb0120","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2026.134588_bb0125","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2026.134588_bb0130","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2026.134588_bb0135","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2026.134588_bb0140","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/eurjpc\/zwae341","article-title":"Intra-individual variability in lipoprotein(a) levels: findings from a large academic health system population","volume":"32","author":"Awad","year":"2025","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.ijcard.2026.134588_bb0145","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jacl.2022.10.004","article-title":"Lipoprotein(a) and inflammation- pathophysiological links and clinical implications for cardiovascular disease","volume":"17","author":"Simantiris","year":"2023","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.ijcard.2026.134588_bb0150","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2026.134588_bb0155","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40265-018-0870-1","article-title":"Effect of Ezetimibe monotherapy on plasma Lipoprotein(a) concentrations in patients with primary hypercholesterolemia: A systematic review and meta-analysis of randomized controlled trials","volume":"78","author":"Awad","year":"2018","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.ijcard.2026.134588_bb0160","first-page":"374","article-title":"Novel therapeutic approaches for the management of elevated lipoprotein(a): From traditional agents to future treatment options","volume":"14","author":"Paragh","year":"2024","journal-title":"Life (Basel)"},{"key":"10.1016\/j.ijcard.2026.134588_bb0165","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.ijcard.2026.134588_bb0170","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ijcard.2026.134588_bb0175","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3390\/medicina60060908","article-title":"Influence of dulaglutide on serum biomarkers of atherosclerotic plaque instability: An interventional analysis of cytokine profiles in diabetic subjects-A pilot study","volume":"60","author":"Hachu\u0142a","year":"2024","journal-title":"Medicina"},{"key":"10.1016\/j.ijcard.2026.134588_bb0180","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"Boffa","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ijcard.2026.134588_bb0185","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4093\/dmj.2023.0277","article-title":"Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism","volume":"48","author":"Bu","year":"2024","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.ijcard.2026.134588_bb0190","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00592-023-02124-w","article-title":"GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform?","volume":"60","author":"Menghini","year":"2023","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.ijcard.2026.134588_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.856111","article-title":"GLP-1 receptor agonists and coronary arteries: From mechanisms to events","volume":"13","author":"Pahud de Mortanges","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijcard.2026.134588_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2025.1545787","article-title":"Can Lp(a) become the next A1C? A case for digital health management tools to overcome inertia to Lipoprotein (a) testing","volume":"12","author":"Wedemeyer","year":"2025","journal-title":"Front. Cardiovasc. Med."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527326004377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527326004377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T06:26:08Z","timestamp":1784528768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527326004377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":40,"alternative-id":["S0167527326004377"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2026.134588","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 receptor agonists associated with better cardiovascular outcomes in obese or diabetic patients with elevated Lp(a) levels: A Multicenter retrospective study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2026.134588","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"134588"}}